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Background: This analysis of patients in a randomized population-based health services study was
done to determine the effects of faecal occult blood test (FOBT) screening of colorectal cancer (CRC)
in outcomes beyond mortality, and to obtain explanations for potential sex differences in screening
effectiveness.
Methods: In the Finnish FOBT screening programme (2004–2011), people aged 60–69 years were
randomized into the screening and control arms. Differences in incidence, symptoms, tumour location,
TNM categories, non-vital outcomes and survival in the screening and control arms were analysed.
Results: From 321 311 individuals randomized, 743 patients with screening-detected tumours and 617
control patients with CRC were analysed. CRC was less common in women than in men (0⋅34 versus 0⋅50
per cent; risk ratio (RR) 0⋅82, 95 per cent c.i. 0⋅74 to 0⋅91) and women were less often asymptomatic
(16⋅7 versus 22⋅0 per cent; RR 0⋅76, 0⋅61 to 0⋅93). Women more often had right-sided tumours (32⋅0
versus 21⋅3 per cent; RR 1⋅51, 1⋅26 to 1⋅80). Among men with left-sided tumours, those in the screening
arm had lower N (RR 1⋅23, 1⋅02 to 1⋅48) and M (RR 1⋅57, 1⋅14 to 2⋅17) categories, as well as a higher
overall survival rate than those in the control arm. Furthermore among men with left-sided tumours,
non-radical resections (26⋅2 versus 15⋅7 per cent; RR 1⋅67, 1⋅22 to 2⋅30) and postoperative chemotherapy
sessions (61⋅6 versus 48⋅2 per cent; RR 1⋅28, 1⋅10 to 1⋅48) were more frequent in the control arm. Similar
benefits of screening were not detected in men with right-sided tumours or in women.
Conclusion: Biennial FOBT screening seems to be effective in terms of improving several different
outcomes in men, but not in women. Differences in incidence, symptoms and tumour location may explain
the differences in screening efficacy between sexes.
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Introduction
Colorectal cancer (CRC) is the third most common cancer
in the world, with 1⋅4 million new cases diagnosed annually
and 0⋅7 million deaths attributed to the disease1. Key
factors that improve the prognosis are early diagnosis and
complete radical tumour resection. However, CRC is often
asymptomatic in its early stages, and is not diagnosed until
symptoms manifest at a later stage2. Several screening
methods have been implemented to detect CRC at early
stages. These include faecal occult blood testing (FOBT),
endoscopy (flexible sigmoidoscopy or colonoscopy), CT
colonography, and combinations thereof3.
Three population-based prospective randomized con-
trolled studies4–6 and one volunteer-based trial7 found
that colorectal tumours can be detected at an earlier stage
and mortality from CRC reduced with biennial FOBT
screening. Biennial FOBT screening reduces CRC mor-
tality by 18 per cent on average8. Sigmoidoscopy as a
screening method has been found to be more effective than
FOBT in reducing CRC mortality9, but carries a small
but significant risk (0⋅08 per cent) of major complications
owing to its invasiveness10. Data regarding colonoscopy as
a population-based screening method are still lacking, and
results of ongoing trials are pending.
In Finland, a prospective randomized population-based
health services programme on CRC screening was
implemented in 200411, with the primary aim of deter-
mining whether CRC screening by biennial FOBT in
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a population-based programme reduces CRC-specific
mortality. The target population was 60–69-year-old men
and women, and the study expanded gradually as more
regions implemented the programme. By the end of 2011,
it covered 41⋅8 per cent of men and 40⋅6 per cent of women
among all 60–69-year-old individuals living in Finland.
The target age limits were chosen based on an earlier
study11 showing that the incidence of CRC and mortality
from the disease increase notably in Finland after the age
of 60 years. Over 80 per cent of new cases were diagnosed
and more than 85 per cent of CRC deaths occurred in
people aged over 60 years11.
The design of the randomized public health programme
and initial mortality results were published recently12.
In contrast with randomized screening trials4,5,7, no sig-
nificant difference in CRC-specific mortality between
the screening and control arms was found12. However,
CRC mortality was reduced in men in the screening arm
compared with controls, and was increased in women,
although the difference between the sexes was not sta-
tistically significant12. Interestingly, other trials13,14 have
reported a greater reduction in CRC mortality in men
undergoing biennial FOBT compared with women,
whereas another15 reported no sex-based difference. It
remains unclear why men appear to benefit more than
women from CRC screening.
The effects of FOBT CRC screening on many important
but non-vital outcomes remain largely unexplored. These
include radical surgery, emergency surgery, and the need
for chemotherapy and a stoma, which are of paramount
interest to healthcare providers and patients alike. The
main aims of the present study were to explore reasons for
the potential sex difference in FOBT screening effective-
ness and to evaluate the effects of screening on non-vital
outcomes.
Methods
This study was approved by the Ministry of Social Affairs
and Health in 2004 (STM/42/07/2004) on the implemen-
tation of CRC screening in Finland, and the approval was
updated in 2010 by the official authority, the National Insti-
tute of Health and Welfare (THL/619/5.05.00/2010).
The design and details of the randomized public health
programme have been reported previously11. Briefly, the
screening population consisted of 60–69-year-old individ-
uals living in municipalities participating in the organized
CRC screening programme. Data from individuals invited
to participate were retrieved from the Central Popula-
tion Registry, and the population was randomized 1 : 1 into
the screening or control arm stratified by birth year, sex
and residence. The randomized programme commenced in
Population sampling n= 321 311
Randomized n= 321 311
Allocated to screening n= 160 762
Received allocated treatment n= 160 762
Allocated to control n= 160 549
Received allocated treatment n= 160 549
Analysed n= 160 719
Excluded n= 43
 Died before randomization (death
 registered after randomization) n= 43
Analysed n= 160 508
Excluded n= 41
 Died before randomization (death
 registered after randomization) n= 41


































Fig. 1 Flow chart of the original study protocol
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 436–447
on behalf of BJS Society Ltd.

























































Fig. 2 Distribution of colorectal cancer in women and in men in the screening and control arms. Percentages in the large bowel refer to
the following areas: appendix, caecum, ascending colon, right transverse colon, left transverse colon, descending colon, sigmoid colon,
rectosigmoid junction, rectum and anus. Percentages in the middle show proportions of right- and left-sided tumours. n.a., Not
available. Risk ratios (RRs), shown with 95 per cent confidence intervals, relate to the proportion of right-sided cancers
September 2004. Screening was performed with a biennial
guaiac FOBT (Hemoccult®; Beckman Coulter, Krefeld,
Germany), which was sent by mail to the screening group.
If there was any blood in the stool, the person was referred
for a full colonoscopy. The screening letter also contained
advice to seek medical attention if any symptoms were
present. All individuals in the screening group were re-
invited every second year until they reached 69 years of age.
The control population was not contacted at all.
The present study included patients diagnosed with
CRC between the time of randomization and the end of
2011 in both the screening and control groups. Patients
diagnosed with CRC from both study arms were identified
from the Finnish Cancer Registry. The registry collects
population-based data on patients with cancer in Finland
with high coverage (97⋅4 per cent) for CRCs16. Patients
randomized to the screening arm were included in this
group for the analyses regardless of active participation,
because all individuals in the screening arm were sent
the letter and FOBT test. Patients were also included in
their study arms regardless of whether the tumour was
found by screening or in spite of it (symptomatic patient
undergoing colonoscopy even though the FOBT was
negative).
Hospitals treating the patients with CRC were identified,
and copies of patients’ medical records were requested.
The following data were extracted manually: clinical and
pathological UICC TNM stage (7th edition)17; symptoms;
extent of surgery; need for emergency surgery, stoma,
or chemotherapy; and histopathological diagnoses. Rad-
ical surgery was defined as complete tumour removal
with tumour-free margins of more than 1 mm after the
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 436–447
on behalf of BJS Society Ltd.
Sex differences in faecal occult blood test screening for colorectal cancer 439
Table 1 Colorectal cancer diagnoses in 2004–2011 in the randomized population of the Finnish colorectal cancer screening
programme: overall sex and study arm differences, and sex differences by study arm in incidence, tumour characteristics, prevalence,
age at diagnosis and symptoms

















No. randomized 79 871 80 891 79 882 80 667
Patients with colorectal
cancer*
442 (0⋅55) 301 (0⋅37) 0⋅67
(0⋅58, 0⋅78)







Right-sided tumour 95 (21⋅5) 92 (30⋅6) 1⋅42
(1⋅11, 1⋅81)







Missing 2 0 1 2
Median age at diagnosis
(years)§






Adenocarcinoma 387 (89⋅8) 247 (84⋅3) 0⋅94
(0⋅89, 0⋅99)







Mucinous adenoma 26 (6⋅0) 35 (11⋅9) 1⋅98
(1⋅22, 3⋅25)







Neuroendocrine 10 (2⋅3) 3 (1⋅0) 0⋅44
(0⋅10, 1⋅43)







Squamous 5 (1⋅2) 4 (1⋅4) 1⋅18
(0⋅29, 4⋅41)







Other 3 (0⋅7) 4 (1⋅4) 1⋅96
(0⋅44, 9⋅90)







Missing 11 8 9 4
Symptoms
Intestinal bleeding 106 (24⋅3) 84 (28⋅0) 1⋅15
(0⋅90, 1⋅47)







Change in bowel habit 104 (23⋅9) 68 (22⋅7) 0⋅95
(0⋅72, 1⋅24)







Total occlusion 6 (1⋅4) 8 (2⋅7) 1⋅94
(0⋅68, 5⋅83)







Anaemia 61 (14) 36 (12⋅0) 0⋅86
(0⋅58, 1⋅25)







Abdominal pain 60 (13⋅8) 68 (22⋅7) 1⋅65
(1⋅20, 2⋅26)







Other 65 (14⋅9) 44 (14⋅7) 0⋅98
(0⋅69, 1⋅40)







No symptoms 163 (37⋅4) 84 (28⋅0) 0⋅75
(0⋅60, 0⋅93)







Missing 6 1 2 5
Values in parentheses are percentage of people with colorectal cancer, except *percentage of people randomized and †95 per cent confidence intervals.
RR, risk ratio. ‡Binomial regression with log-link function, except §difference in medians analysed by quantile regression; adjusted for ¶sex and #study
arm. **Significant at 5 per cent false discovery rate based on Benjamini–Hochberg criterion.
primary surgery. Emergency surgery was defined as a colo-
rectal operation during an emergency admission. Stomas
included both loop and end stomas as well as permanent
or temporary stomas. Chemotherapy included both adju-
vant therapy administered after curative surgery and ther-
apy administered for metastatic CRC. Dates of death were
collected from the Central Population Registry until the
end of 2015. This observational analysis was planned after
the original trial had been completed.
Statistical analysis
Sex differences in incidence, histology, treatments, symp-
toms and laterality were estimated by risk ratios (RRs) using
log-link binomial regression, and in median age at diag-
nosis using quantile regression. These sex differences were
adjusted for study arm. Study arm differences in non-vital
outcomes were also estimated using RRs for all patients,
by sex, and by both sex and tumour laterality (right-sided
versus left-sided). Overall study arm differences in non-vital
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Table 2 Differences between randomization arms in T, N, and M categories by both laterality and sex, by laterality and overall
Right Left


















T≤2 22 (26) 9 (13) 20 (23) 10 (14) 140 (43⋅1) 73 (27⋅2) 71 (39⋅4) 36 (23⋅5)
T>2 63 (74) 59 (87) 66 (77) 61 (86) 185 (56⋅9) 195 (72⋅8) 109 (60⋅6) 117 (76⋅5)
Missing 10 8 6 15 20 17 29 14
RR (control versus screening)*















N0 48 (59) 38 (58) 43 (52) 32 (46) 194 (61⋅0) 138 (52⋅1) 94 (54⋅0) 82 (55⋅4)
N≥ 1 33 (41) 28 (42) 39 (48) 37 (54) 124 (39⋅0) 127 (47⋅9) 80 (46⋅0) 66 (44⋅6)
Missing 14 10 10 17 27 20 35 19
RR (control versus screening)*















M0 70 (76) 57 (75) 64 (70) 60 (71) 289 (84⋅5) 215 (75⋅7) 173 (82⋅8) 123 (74⋅5)
M1 22 (24) 19 (25) 28 (30) 25 (29) 53 (15⋅5) 69 (24⋅3) 36 (17⋅2) 42 (25⋅5)
Missing 3 0 0 1 3 1 0 2
RR (control versus screening)*














Values in parentheses are percentages unless indicated otherwise; *values in parentheses are 95 per cent confidence intervals. †Risk ratio (RR) estimated
separately by sex and laterality for each stage category. ‡RR adjusted for sex and estimated separately by laterality for each stage category. §RR adjusted
for sex and laterality, and estimated separately for each stage category response. A RR above 1 indicates a greater prevalence of the higher T, N or M
category in control versus screening group.
outcomes were estimated with adjustment for T category
(T0–2 or T3–4).
Differences between the sexes in variables described
above were also estimated separately by study arm. Preva-
lence differences between study arms were estimated with
regard to histology, symptoms, laterality and TNM cate-
gories. TNM category analysis was also stratified by sex,
and both sex and laterality. These estimates were adjusted
for sex, laterality, or both where they were not stratified
by these variables. Simple proportions of tumour loca-
tions were computed by sex and study arm. Stratifying by
both sex and laterality, survival was estimated for the study
arms using the Kaplan–Meier method, and differences in
patient survival between the study arms were estimated by
means of hazard ratios (HRs) derived using Cox regression.
Follow-up commenced at the time of diagnosis of CRC and
ended upon death, emigration or on 31 December 2015,
whichever was earliest.
Confidence intervals were estimated for all RRs and
HRs at the 95 per cent confidence level. No estimate was
adjusted for age because age adjustment had no effect.
P values were estimated using two-sided tests for the
main results, unstratified sex differences and all study arm
differences in non-vital outcomes. In addition, multiple
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 436–447
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a  Non-radical surgery
b  Emergency surgery
c  Chemotherapy




















Control better Screening better










































Control better Screening better










































Control better Screening better
1·2 1·3 1·4 1·5 1·61·0 1·1
98 of 160
Fig. 3 Effect of faecal occult blood test screening on non-vital outcomes, overall, by sex, and by both sex and laterality: a non-radical
surgery, b emergency surgery, c chemotherapy and d stoma. Risk ratios are shown with 95 per cent confidence intervals for the control
versus screening arms (log-link binominal regression); *significant at 5 per cent false discovery rate based on Benjamini–Hochberg
criterion
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Control better Screening better
1·4 1·6 1·8 2·0 2·2 2·41·0 1·2
62 of 158
Fig. 3 Continued
comparisons were taken into account by considering
significant only the results that were accepted at a 5 per
cent false detection rate based on the Benjamini–Hochberg
criterion (BH+). All statistical analyses were performed
using SPSS® version 24 (IBM, Armonk, New York, USA)
or R version 3.4.0 (packages Epi 2.16, quantreg 5.3 and
survival 2.41.3; https://www.r-project.org/).
Results
Between 2004 and 2011, 321 311 people were random-
ized into the screening or control arm. Owing to a delay
between population sampling from the Central Population
Registry and randomization, patients who had died before
the randomization date (43 in the screening arm and 41
in the control arm) were excluded from the analyses. Thus,
there were 160 719 and 160 508 individuals in the screening
and control arms respectively (Fig. 1). The screening par-
ticipation rate (individuals who returned the FOBT) was
69⋅2 per cent (men, 61⋅9 per cent; women, 76⋅3 per cent),
and the proportion of positive FOBT results was 2⋅7 per
cent in women and 4⋅7 per cent in men. The compliance
rate for further colonoscopy was 84⋅6 per cent (proportion
of people with a positive FOBT who actually underwent
colonoscopy).
A total of 743 and 617 CRCs were detected in the screen-
ing and control arms respectively between 2004 and the end
of 2011. Women were less often diagnosed with CRC than
men: prevalence 0⋅37 versus 0⋅55 per cent respectively in the
screening arm and 0⋅32 versus 0⋅45 per cent in the control
arm (RR 0⋅82, 95 per cent c.i. 0⋅74 to 0⋅91; BH+). Women
had more mucinous subtype adenocarcinomas than men:
60 (11⋅0 per cent) versus 51 (6⋅5 per cent) (RR 1⋅70, 1⋅19
to 2⋅43; BH+). Tumours were more often located on the
right side in women than in men (RR 1⋅51, 1⋅26 to 1⋅80;
BH+). The proportion of right- and left-sided tumours did
not differ between the study arms (RR 1⋅05, 0⋅88 to 1⋅25)
(Fig. 2 and Table 1).
Symptoms
Almost none of the patients in the control arm were asymp-
tomatic. There were 247 asymptomatic patients (33⋅6 per
cent) in the screening arm and only 20 (3⋅3 per cent) in
the control arm (RR 0⋅10, 95 per cent c.i. 0⋅06 to 0⋅15)
(Table 1). Women were less often asymptomatic than men
(RR 0⋅76, 0⋅61 to 0⋅93; BH+) but, of individual symptoms,
only the prevalence of abdominal pain was significantly dif-
ferent between the sexes (RR 1⋅36, 1⋅12 to 1⋅67; BH+). The
most common symptom in both study arms was intestinal
bleeding (32⋅4 per cent) followed by a change in bowel
habit (29⋅6 per cent), abdominal pain (21⋅9 per cent) and
anaemia (16⋅6 per cent).
TNM stage
Cancers from the screening arm had a lower T category
(RR 1⋅25, 95 per cent c.i. 1⋅16 to 1⋅35), N category (RR
1⋅14, 1⋅00 to 1⋅29) and M category (RR 1⋅33, 1⋅08 to 1⋅62)
than those from the control arm (Table 2). In subgroup
analyses, left-sided tumours in the screening arm had a
lower T category (RR 1⋅30, 1⋅18 to 1⋅43), N category (RR
1⋅16, 1⋅00 to 1⋅35) and M category (RR 1⋅53, 1⋅19 to 1⋅97)
than those in the control arm, whereas right-sided tumours
had only a lower T category (RR 1⋅14, 1⋅02 to 1⋅28), but
not N or M category in the screening arm. In women, the
only differences between study arms were in the T and
M categories of left-sided tumours. However, men with
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Fig. 4 Overall survival after diagnosis of colorectal cancer in the screening and control groups: a men with right-sided tumours, b men
with left-sided tumours, c women with right-sided tumours and d women with left-sided tumours analysis (follow-up data missing for 1
patient)
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left-sided tumours had higher T, N and M categories in the
control arm, whereas men with right-sided tumours had
only a higher T category in control arm.
Non-vital outcomes
Patients with CRC in the control arm experienced signifi-
cantly more non-radical surgery (26⋅8 versus 19⋅2 per cent;
RR 1⋅39, 95 per cent c.i. 1⋅14 to 1⋅70; BH+), emergency
surgery (14⋅1 versus 9⋅3 per cent; RR 1⋅51, 1⋅11 to 2⋅06;
BH+) and administration of postoperative chemotherapy
(62⋅8 versus 52⋅1 per cent; RR 1⋅20, 1⋅09 to 1⋅32; BH+)
than those in the screening arm (Fig. 3). Controls also had
more stomas, but this was not significant according to the
Benjamini–Hochberg criterion (32⋅8 versus 27⋅3 per cent;
RR 1⋅21, 1⋅02 to 1⋅43). After adjustment for T category
(T0–2 versus T3–4), no significant differences were found
in the rates of non-radical surgery (RR 1⋅13, 0⋅91 to 1⋅41),
emergency surgery (RR 1⋅17, 0⋅85 to 1⋅61), postoperative
chemotherapy (RR 0⋅99, 0⋅92 to 1⋅08) or stomas (RR 1⋅17,
0⋅98 to 1⋅39). In separate analyses of men and women, a
statistically significant improvement in these non-vital out-
comes was observed only in men.
Further subgroup analyses of left- and right-sided
tumours indicated that the findings were restricted mainly
to left-sided cancers. An exception was observed in men
with right-sided tumours, who had emergency surgery sig-
nificantly more often in the control arm compared with the
screening arm (33 versus 15 per cent; RR 2⋅15, 1⋅20 to 4⋅07;
BH+). Significantly more men with left-sided tumours in
the control group than the screening group underwent
non-radical surgery (26⋅2 versus 15⋅7 per cent; RR 1⋅67,
1⋅22 to 2⋅30; BH+) and postoperative chemotherapy (61⋅6
versus 48⋅2 per cent; RR 1⋅28, 1⋅10 to 1⋅48; BH+), and the
stoma rate was increased but not significantly according to
the Benjamini–Hochberg criterion (45⋅4 versus 36⋅1 per
cent; RR 1⋅26, 1⋅04 to 1⋅53).
Survival
Survival was worse in controls than in the screening arm
in men with CRC (hazard ratio (HR) 1⋅31, 95 per cent c.i.
1⋅05 to 1⋅64), but not in women (HR 1⋅07, 0⋅80 to 1⋅45).
Among men, the 5-year overall survival (OS) rates were
68⋅8 versus 61⋅5 per cent in the screening versus control
arms respectively, compared with 70⋅7 versus 71⋅5 per cent
in women. Among men with left-sided tumours, survival
was better in the screening arm than the control arm
(HR 1⋅37, 1⋅06 to 1⋅77), but not in men with right-sided
tumours (HR 1⋅19, 0⋅75 to 1⋅89) (Fig. 4a,b). Five-year OS
rates in men with left-sided tumours were 70⋅0 per cent in
the screening arm versus 62⋅1 per cent in the control arm;
respective rates in men with right-sided tumours were
65 versus 59 per cent. In women, survival was similar in
the screening and control arms regardless of whether the
tumour was located on the right side (5-year OS rate 66
versus 67 per cent respectively; HR 1⋅19, 0⋅73 to 1⋅92) or
left side (72⋅8 versus 74⋅9 per cent; HR 0⋅96, 0⋅65 to 1⋅41)
(Fig. 4c,d). Interestingly, the 5-year OS rate in women both
in the screening and control arms was similar to that of
men in the screening arm (70⋅7, 71⋅5 and 68⋅8 per cent
respectively).
Discussion
These data on biennial FOBT screening are based on the
largest population-based randomized health services study,
covering over 40 per cent of 60–69-year-old people living
in Finland. The analysis revealed several important find-
ings. There were substantial sex differences in laterality,
histology and symptoms. Improvements in non-vital out-
comes were observed in the screening group, but primarily
in men with left-sided CRC. Additional analyses showed
that men with left-sided tumours gained benefits from the
screening in terms of lower TNM stage and better survival.
There are several possible explanations for the observed
discrepancy according to sex. Colorectal tumours in
women were more often located on the right side of
the colon, as has been reported previously18–20. Longer
passage of faecal blood may lower the sensitivity of the
test and produce a false-negative result; this is supported
by the fact that, although screening uptake was higher
in women (76⋅3 versus 61⋅9 per cent), positive results
were less frequent than in men (2⋅7 versus 4⋅7 per cent).
The finding that FOBT screening seemed ineffective in
women could be related to the fact that women had more
right-sided tumours and that screening with FOBT can be
ineffective in detecting early right-sided colonic cancers in
either sex. In addition, more women in the screening arm
were symptomatic (abdominal pain), indicating that they
might be more sensitive to the symptoms of CRC. Men
who may not experience symptoms or who ignore them
might benefit more from screening. It is interesting to
note that even the higher participation rates in women did
not translate into beneficial outcomes, further supporting
the notion that FOBT screening is ineffective in women. It
was also found that screening benefits men with left-sided
CRC across all TNM categories, but among women with
left-sided tumours only the T and M categories were lower
in the screening group versus controls. This could indi-
cate a difference in the biology of tumour dissemination
between men and women. The improvements in survival
and non-vital outcomes in men with left-sided tumours are
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most likely due to lower TNM stage in this subgroup. This
is supported by the finding that the observed differences
disappeared when outcomes were adjusted for T category.
Fewer CRCs were detected in women in both study arms,
which may be attributed to the fact that the incidence
increases with age21 and this increase has been reported
to occur later in women22. Although the set age range
for screening (60–69 years) appears to be sufficient for
substantial improvements for men, women might benefit
from screening at an older age.
The strength of this study is its findings regarding param-
eters that were not investigated in earlier FOBT screening
trials4–7. In addition to survival benefits, it is important to
know the influence of screening on other important mea-
sures, such as stomas, which are associated with reduced
quality of life23 and commonly cause complications (21–70
per cent)24. These were reduced in the screening arm in
men, although the reduction was not statistically signif-
icant according to the Benjamini–Hochberg criterion.
From the point of view of healthcare expenditure, it is also
crucial to determine the proportion of emergency surgery
and the need for postoperative chemotherapy, as both
increase costs and potentially influence patients’ quality
of life. Non-radical and emergency surgery was rarer in
the screening arm than in the control arm among men.
Another retrospective study25 comparing two cohorts
from different eras found a similar reduction in emergency
surgery in patients undergoing CRC screening. In addition
to increased costs, emergency resections have a negative
impact on survival compared with elective resections26,27.
The largest randomized FOBT trials were half the size
of the present randomized health services study on CRC
screening (Nottingham trial, 152 850 individuals; Göte-
borg trial, 68 308; Funen trial, 61 933; Minnesota trial,
46 551)4–7. A meta-analysis8 that included the latest data
from these trials estimated the reduction in CRC-specific
mortality to be 18 per cent, but no reduction in overall mor-
tality was found in an intention-to-treat analysis. The Not-
tingham trial15 reported CRC mortality ratios for men and
women separately and, in contrast to the present authors’
previous finding12, there was no difference between men
and women (RR for screening versus control arm 0⋅90 in
women and 0⋅91 in men). However, the Minnesota trial13
reported that the reduction in CRC mortality was larger
for men than for women.
Tumour location appeared to be the most likely expla-
nation for the sex disparity observed in the present study.
Only men with left-sided tumours had improved survival
and lower TNM categories in the screening arm compared
with the control arm. The Nottingham trial15 reported
similar RRs for screened versus control populations for
CRC mortality in the proximal (to the sigmoid colon)
and distal colorectum (RR 0⋅93 and 0⋅89 respectively),
but both sexes were analysed together. The Funen trial28
revealed that FOBT screening tended to reduce mortality
rates among patients with proximal compared with distal
tumours, but the difference was not significant (P = 0⋅13).
Although most CRCs are left-sided, the present results
suggest that FOBT is ineffective for screening right-sided
tumours.
In addition to the guaiac FOBT used here and in other
trials, the faecal immunochemical test (FIT) has also been
used for CRC screening. FIT has a high specificity, but ran-
domized screening trials of its effectiveness are lacking29.
Therefore, it is not yet possible to compare fully the effec-
tiveness of FOBT and FIT as a screening method. Flexible
sigmoidoscopy has been shown to reduce CRC mortal-
ity by 21 per cent, on average, in randomized screening
trials9. Colonoscopy is recommended if polyps are discov-
ered during sigmoidoscopy in such trials. Thus, patients
with positive sigmoidoscopy findings will require a sec-
ond bowel preparation and two appointments, compared
with one for patients with a positive FOBT. In theory, the
screening method that should improve the outcomes of
patients with right-sided CRC is colonoscopy; however,
this procedure is invasive, more expensive, requires more
healthcare resources and might attract fewer participants
than FOBT. CT colonography might be more favourable
in this regard, but has other specific disadvantages (such as
radiation exposure), and its efficacy as a screening method
has not yet been investigated30. Although randomized tri-
als of colonoscopy for screening are ongoing, no results
have been published to date. As the results of the Finnish
randomized programme using FOBT as the primary test
did not find a difference between arms in CRC-specific or
overall mortality12, CRC screening was stopped in Finland
in 2014. Currently, implementation of more individualized
screening programmes is under consideration.
This study has several limitations. Some of the
screen-detected cancers may have been overdiagnosed,
although it is likely that the proportion of overdiagnoses
is low. In the Minnesota trial31, only 6–9 per cent of
screen-detected cases were estimated to be overdiagnoses.
In the Nottingham trial32, little evidence was found in
support of an overdiagnosis bias. The present data suggest
that roughly 30 per cent of cancers were screen-detected
in the screening arm (difference between proportions of
asymptomatic cases in the study arms, 33⋅6 – 3⋅3= 30⋅3
per cent). Even if 10 per cent of screen-detected cases were
overdiagnosed, this would still represent only 3 per cent
of all cases in the screening arm. Therefore, any bias from
overdiagnosis is likely to be small. Furthermore, estimates
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 436–447
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for sex differences were adjusted for study arm, which
further reduces such bias.
Survival analyses are also affected by lead time bias, the
magnitude of which remains unclear. However, as survival
did not improve significantly in women, even with bias
owing to overdiagnosis and lead time, it is even clearer
that FOBT screening is not beneficial in women. Further-
more, the present study was a retrospective cross-sectional
analysis of patients diagnosed with CRC within the popu-
lation based on a randomized health services study, where
the diagnostic and treatment strategies in different hospi-
tals were not standardized. On the other hand, the study
design was pragmatic, and is thus more likely to represent
real-life clinical care scenarios.
Even though over 320 000 people were randomized and
more than 1300 patients with CRC were analysed, sub-
group analyses might have suffered from lack of statis-
tical power. Many of the effects in women were in the
same direction as those in men, but remained statistically
non-significant. Should there be any significant effect if
larger groups were analysed, the clinical relevance would
still be minor. This is also reflected in the survival curves,
which are identical in the screening and control arms in
women. Survival improvements occurring contemporane-
ously with adoption of the Finnish screening programme
in the municipality were observed in patients with CRC
not invited for screening33. Such an improvement in the
control population would be likely to also translate to
improvements in controls in non-vital outcomes and cancer
stage. Therefore, the control versus screening comparisons
reported here probably understate the effect of the screen-
ing programme on such outcomes.
This investigation of patients with CRC, based on a
large population-based randomized health services study,
found biennial guaiac FOBT screening to be associated
with lower proportions of non-radical surgery, emer-
gency surgery and postoperative chemotherapy, as well as
improved TNM categories and OS, in men. Improvements
were observed mainly in patients with left-sided tumours.
FOBT screening did not appear to be associated with
lower TNM categories or survival among 60–69-year-old
women with CRC. Therefore, screening by different
methods or at different intervals or ages should be con-
sidered among women. The sex discrepancy in outcomes
may be due to factors related to the incidence, symptoms
and location of colorectal tumours.
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ZA, Chen DC et al. Sex-specific differences in colon cancer
when quality measures are adhered to: results from
international, prospective, multicenter clinical trials. J Am
Coll Surg 2017; 225: 85–92.
21 Brændegaard Winther S, Baatrup G, Pfeiffer P, Qvortrup C.
Academy of Geriatric Cancer Research (AgeCare). Trends in
colorectal cancer in the elderly in Denmark, 1980–2012.
Acta Oncol 2016; 55(Suppl 1): 29–39.
22 Brenner H, Hoffmeister M, Arndt V, Haug U. Gender
differences in colorectal cancer: implications for age at
initiation of screening. Br J Cancer 2007; 96: 828–831.
23 Vonk-Klaassen SM, de Vocht HM, den Ouden ME, Eddes
EH, Schuurmans MJ. Ostomy-related problems and their
impact on quality of life of colorectal cancer ostomates: a
systematic review. Qual Life Res 2016; 25: 125–133.
24 Shabbir J, Britton DC. Stoma complications: a literature
overview. Colorectal Dis 2010; 12: 958–964.
25 Askari A, Nachiappan S, Currie A, Bottle A, Abercrombie J,
Athanasiou T et al. Who requires emergency surgery for
colorectal cancer and can national screening programmes
reduce this need? Int J Surg 2017; 42: 60–68.
26 Bass G, Fleming C, Conneely J, Martin Z, Mealy K.
Emergency first presentation of colorectal cancer predicts
significantly poorer outcomes: a review of 356 consecutive
Irish patients. Dis Colon Rectum 2009; 52: 678–684.
27 McArdle CS, Hole DJ. Emergency presentation of colorectal
cancer is associated with poor 5-year survival. Br J Surg
2004; 91: 605–609.
28 Kronborg O, Jørgensen OD, Fenger C, Rasmussen M.
Randomized study of biennial screening with a faecal occult
blood test: results after nine screening rounds. Scand
J Gastroenterol 2004; 39: 846–851.
29 Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy
of fecal immunochemical tests for colorectal cancer:
systematic review and meta-analysis. Ann Intern Med 2014;
160: 171.
30 Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C,
Inadomi JM, Kim LS et al. Screening for colorectal cancer
and evolving issues for physicians and patients: a review.
JAMA 2016; 316: 2135–2145.
31 Luo D, Cambon AC, Wu D. Evaluating the long-term effect
of FOBT in colorectal cancer screening. Cancer Epidemiol
2012; 36: e54–e60.
32 Robinson MH, Hardcastle JD, Moss SM, Amar SS,
Chamberlain JO, Armitage NC et al. The risks of screening:
data from the Nottingham randomised controlled trial of
faecal occult blood screening for colorectal cancer. Gut 1999;
45: 588–592.
33 Miettinen J, Malila N, Hakama M, Pitkäniemi J. Spillover
improved survival in non-invited patients of the colorectal
cancer screening programme. J Med Screen 2018; 25:
134–140.
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 436–447
on behalf of BJS Society Ltd.
